Christoph John Sayed MD

Professor of Dermatology

101 Manning DrDepartment of Internal MedicineChapel Hill, NC 27514
Phone+1 919-966-1072
Fax+1 919-843-2356

Dr. Sayed is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sayed's full profile Already have an account?

Summary

Dr. Christoph Sayed is a dermatologist based in Chapel Hill, NC, specializing in general and complex medical dermatology. He completed his dermatology residency and internal medicine internship at University of North Carolina Hospitals, where he also earned his medical degree in 2009. Dr. Sayed has published extensively on hidradenitis suppurativa, with recent articles appearing in JAMA Dermatology, Dermatology and Therapy, and The British Journal of Dermatology. He has conducted clinical trials on treatments for hidradenitis suppurativa and holds multiple certifications in CMS Meaningful Use from Epic Systems Corporation.

Education & Training

University of North Carolina HospitalsResidency, Dermatology, 2010 - 2013
University of North Carolina HospitalsInternship, Internal Medicine, 2009 - 2010
University of North Carolina at Chapel Hill School of MedicineClass of 2009

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NC State Medical License 2009 - 2027
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.
COMPLETED
NA

Publications & Presentations

PubMed

Patients' Preferences for Surgical Procedures in Hidradenitis Suppurativa: A Discrete Choice Experiment.
Katja C Heinz, Emily G Summers, Charlotte Beaudart, Teja Mallela, Stephanie Goldberg
The Patient. 2026-09-01
Defining clinically meaningful benefit in mild-to-moderate hidradenitis suppurativa trials.
Rahib K Islam, Lacey M Falgout, Nicholas J Culotta, Christopher J Sayed, Christopher J Haas
Journal of the American Academy of Dermatology. 2026-08-21
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
Martina L Porter, Antonio Martorell, Christopher J Sayed, Falk G Bechara, Hadar Lev-Tov
Nature Medicine. 2026-08-01

Books/Book Chapters

Reichel’s Care for the Elderly, 7th ed.
Chapter: Geriatric Dermatology
Sayed C, Varman K.Editors: Busby-Whitehead J, Arenson C.. Cambridge University Press, New York2016
Frontiers in Gastrointestinal Research.
Chapter: Psoriasis-like Lesions and Skin Reactions (Chapter). In Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Disease.
Page 119 - 125Herfarth H, Long M, Sayed C.Editors: Rogler G, Herfarth H, Toshifumi H, Nielsen OH..KargerEdition 34,2015
Pathology: A Modern Case Study.
Chapter: Pathology of the Skin
Miedema J, Sayed C, Zedek D.Editors: Reisner, H..McGraw-Hill. , New YorkEdition 1,2014

Lectures

Advanced Management Strategies for Hidradenitis Suppurativa
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
Development of the North American Clinical Guidelines for Hidradenitis Suppurativa
American Academy of Dermatology Annual Meeting, Orlando, FL. - 2/2018
Office-Based Procedures for Hidradenitis Suppurativa
American Academy of Dermatology Annual Meeting, Orlando, FL - 2/2018

Press Mentions

Can Endocrine-Disrupting Chemicals from Plastics Increase HS Risk?December 8th, 2025
When Your HS Treatments Stop Working: Finding New Paths to ReliefOctober 30th, 2025
Hidradenitis Suppurativa Genetics Point Toward the Hair Growth CycleJune 13th, 2025

Grant Support

Determining the Genetic Basis of Hidradenitis SuppurativaUNIV OF NORTH CAROLINA CHAPEL HILL2024–2029
Determining the Genetic Basis of Hidradenitis SuppurativaUNIV OF NORTH CAROLINA CHAPEL HILL2024–2029

Research History

Co-investigatorA Phase 4, Double-Blind, Randomised,Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa.2018 - Present
Principal InvestigatorGenome-wide association study of patients with hidradenitis suppurativa.2018 - Present
Principal Investigator• UCB Biopharma SPRL, HS0001, A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Pharmacokinetics Of Bimekizumab In Subjects With Moderate To Severe Hidradenitis Suppurativa (HS).2018 - Present
Principal InvestigatorA randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa (SHINE). 2018.2018 - Present
Co-investigatorA Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® (halobetasol propionate) Cream, 0.05% in the Treatment of Plaque Psoriasis.2017 - Present